Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.

Cancer Med · 2020 · PMC7333856 · PMID 32352244

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

A particularly interesting signal was derived from comparative analyses of the predefined molecular subgroups of PIKTAM, which support the concept of precision oncology in HR + mBC: In patients with tumors harboring oncogenic PIK3CA mutations, a clear trend of improved outcomes with buparlisib/tamoxifen treatment was observed.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.